Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature

References

• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [Clinical trial, phase III comparative study multicenter study randomized controlled trial research support, non-U.S. Gov’t]. Blood. 2013;122:4047–4053.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial [Clinical trial, phase III multicenter study randomized controlled trial research support, non-U.S. Gov’t]. JCO. 2013;31:1285–1292.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts [Comparative study randomized controlled trial research support, non-U.S. Gov’t]. Blood. 2014;123:1833–1835.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Haematologica. 2013;98:1865–1871.
   PubMed Web of Science ®Google Scholar
• McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10:370–379.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–435.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Kadia T, et al. A phase I/II study of the janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia [Clinical trial, phase I clinical trial, phase II research support, N.I.H., extramural research support, non-U.S. Gov’t]. Clin Lymphoma Myeloma Leuk. 2015;15:171–176.
   PubMed Web of Science ®Google Scholar
• Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms [Research support, non-U.S. Gov’t]. Cancer Res. 2015;75:2187–2199.
   PubMed Web of Science ®Google Scholar
• Parampalli Yajnanarayana S, Stubig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms [research support, non-U.S. Gov’t]. Br J Haematol. 2015;169:824–833.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo [In vitro research support, non-U.S. Gov’t]. Blood. 2013;122:1192–1202.
   PubMed Web of Science ®Google Scholar
• Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56:1528–1529.
   PubMed Web of Science ®Google Scholar
• Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib [Case reports letter]. Leukemia. 2014;28:1750–1751.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Catani L, et al. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94:519–520.
   PubMed Web of Science ®Google Scholar
• Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014;2014.doi: 10.1136/bcr-2014-204950.
   Google Scholar
• Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? [Letter]. Blood. 2013;122:3843–3844.
   PubMed Web of Science ®Google Scholar
• Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment [Case reports letter]. J Am Acad Dermatol. 2014;70:e59–e60.
   PubMed Web of Science ®Google Scholar
• Shen CH, Hwang CE, Chen YY, et al. Hepatitis B virus reactivation associated with ruxolitinib [Case reports letter]. Ann Hematol. 2014;93:1075–1076.
   PubMed Web of Science ®Google Scholar
• Islam R, Yellu MR, Rafiullah, et al. Low-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis [Case reports]. BMJ Case Rep. 2013;2013. doi:10.1136/bcr-2013-010068.
   Google Scholar
• Kinoshita M, Ogawa Y, Kawamura T, et al. Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor. J Dermatol. 2016;43:1387–1388.
   PubMed Web of Science ®Google Scholar
• Chan JF, Chan T, Gill H, et al. Disseminated infections with talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. 2015;21:1101–1106.
   PubMed Web of Science ®Google Scholar
• Stansfield LC, Begna K, Tosh P, et al. Mucormycosis in a patient treated with ruxolitinib [E-letter]. Blood. 2014;2014.
   Google Scholar
• Landman GW, Arend SM, van Dissel JT. Ruxolitinib can mask symptoms and signs of necrotizing fasciitis [Case reports letter]. J Infect. 2013;66:296–297.
   PubMed Web of Science ®Google Scholar
• Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol. 2016;95:361–362.
   PubMed Web of Science ®Google Scholar
• von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus retinitis in a patient who received ruxolitinib [Case reports letter]. N Engl J Med. 2016;374:296–297.
   PubMed Web of Science ®Google Scholar
• Palmason R, Linden O, Richter J. Case-report: EBV driven lymphoproliferative disorder associated with ruxolitinib. BMC Hematol. 2015;15:10.
   PubMedGoogle Scholar
• Shamil E, Cunningham D, Wong BL, et al. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis. 2015;2015:284168.
   PubMedGoogle Scholar
• Keizer S, Gerritsen R, Jauw Y, et al. [Fatal tuberculosis during treatment with ruxolitinib] [Case reports]. Ned Tijdschr Geneeskd. 2015;159:A8650.
   PubMedGoogle Scholar
• Lee SR, Park Y, Choi CW, et al. Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment. Blood. 2013;122:1596–1596.
   Web of Science ®Google Scholar
• Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55:1341–1344.
   PubMed Web of Science ®Google Scholar
• Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016;2016:2389038.
   PubMedGoogle Scholar
• Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95:1207–1209.
   PubMed Web of Science ®Google Scholar
• Kusano Y, Terui Y, Ueda K, et al. Epstein-barr virus gastric ulcer associated with ruxolitinib. Ann Hematol. 2016;95:1741–1742.
   PubMed Web of Science ®Google Scholar
• Kusano Y, Terui Y, Ueda K, et al. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib. Ann Hematol. 2016;95:1561–1562.
   PubMed Web of Science ®Google Scholar
• Eyal O, Flaschner M, Ben Yehuda A, et al. Varicella‐zoster virus meningoencephalitis in a patient treated with ruxolitinib. Am J Hematol. 2017;92:E74–E75.
   PubMed Web of Science ®Google Scholar
• Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report [Case reports]. BMC Res Notes. 2012;5:552.
   PubMedGoogle Scholar
• Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis [Letter]. Leukemia. 2014;28:225–227.
   PubMed Web of Science ®Google Scholar
• Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib [Case reports letter research support, non-U.S. Gov’t]. N Engl J Med. 2013;369:197–198.
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib [Case reports letter research support, non-U.S. Gov’t]. N Engl J Med. 2013;369:681–683.
   PubMed Web of Science ®Google Scholar
• Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor [Case reports]. Chest 2013;143:1478–1479.
   PubMed Web of Science ®Google Scholar